Purodiol

Purodiol Do Brasil was a Brazil-based company supplying cannabinoid pharmaceutical products to patients under ANVISA regulations. Publicly available transaction descriptions indicate the business was involved in multiple clinical studies and trials in Brazil, while also generating commercial revenue from pharmaceutical product supply. In 2018, Isodiol International acquired 99% of Purodiol Do Brasil as part of its acquisition of Biosynthesis Pharma Group-related assets. Separate UK entity records for Purodiol Ltd show that company was later dissolved in 2020, and current public evidence for ongoing standalone operations is limited. Overall, Purodiol appears to have operated as a cannabinoid-focused healthcare/pharma business rather than a traditional venture-stage biotech developer.